Novel extended release budesonide formulation for treatment of ulcerative colitis.
BACKGROUND
Budesonide , a synthetic, non-halogenated corticosteroid, has been introduced in the topical treatment of ulcerative colitis (UC). Budesonide MMX, a novel, once-daily oral formulation of budesonide that uses a multi-matrix system (MMX) technology to extend the release of budesonide throughout the colon proved to be effective for the treatment of active UC. The focus of this review is the current status of budesonide MMX in extensive and left-sided UC.


METHODS
This paper covers the recent studies of budesonide MMX to describe its efficacy and safety in the treatment of mild-to-moderately active left-sided UC. A literature search and review of budesonide MMX were carried out using the PubMed database up to August 2013.


CONCLUSIONS
Clinical studies of budesonide MMX in adults with mild-to-moderately active UC demonstrated its efficacy and tolerability in achieving clinical and endoscopic remission. Although one trial is still ongoing, budesonide MMX 9 mg tablets represented the first orally administered topical corticosteroid formulation targeting the entire colon for the management of patients with active, mild-to-moderate UC.
University of Szeged, First Department of Medicine , 8-10 Koranyifasor, Szeged, H6720 , Hungary molnar.tamas@med.u-szeged.hu.
Klaudia
K
Farkas
Tamás
T
Molnár
D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019819:Budesonide / Q000494:pharmacology / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003692:Delayed-Action Preparations / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans
D000893:Anti-Inflammatory Agents; D003692:Delayed-Action Preparations; D019819:Budesonide